Login to Your Account

'Correct' CF Phase II Answer: Vertex Steps to Head of Class?

By Randy Osborne
Staff Writer

Monday, April 22, 2013
Vertex Pharmaceuticals Inc.'s approach to cystic fibrosis (CF) – pairing the approved therapy Kalydeco (ivacaftor) as a "potentiator" with another compound, VX-661, as a "corrector" – gained market-pleasing, top-line, Phase II proof that sent the stock on a skyward ride.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription